# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059072
Filing Date
2024-05-14
Accepted
2024-05-14 07:06:14
Documents
65
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | mura-20240331.htm iXBRL | 10-Q | 1653739
2 | EX-31.1 | mura-ex31_1.htm | EX-31.1 | 15399
3 | EX-31.2 | mura-ex31_2.htm | EX-31.2 | 15450
4 | EX-32.1 | mura-ex32_1.htm | EX-32.1 | 9416
5 | EX-32.2 | mura-ex32_2.htm | EX-32.2 | 9468
| Complete submission text file | 0000950170-24-059072.txt |  | 5853171

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | mura-20240331.xsd | EX-101.SCH | 828928
68 | EXTRACTED XBRL INSTANCE DOCUMENT | mura-20240331_htm.xml | XML | 758497

Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41837 | Film No.: 24941429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)